Patents by Inventor Stacie S. CANAN

Stacie S. CANAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES
    Publication number: 20230146944
    Abstract: Provided herein are Heterocyclic compounds of formula I: and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.
    Type: Application
    Filed: October 4, 2022
    Publication date: May 11, 2023
    Inventors: Natalie Hawryluk, Stacie S. Canan, Kevin R. Condroski, Graham Kyne, Matthew Bedore, Sanjay Menon
  • Heterocyclic compounds and their use for treatment of helminthic infections and diseases
    Patent number: 11505548
    Abstract: Provided herein are Heterocyclic compounds of formula I: and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 22, 2022
    Assignees: CELGENE CORPORATION, ZOETIS LLC
    Inventors: Natalie Hawryluk, Stacie S. Canan, Kevin R. Condroski, Graham Kyne, Matthew Bedore, Sanjay Menon
  • Animal and human anti-malarial agents
    Patent number: 11344554
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: May 31, 2022
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk
  • HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES
    Publication number: 20200339559
    Abstract: Provided herein are Heterocyclic compounds of formula I: and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R1, R2, and RN are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 29, 2020
    Inventors: Natalie Hawryluk, Stacie S. Canan, Kevin R. Condroski, Graham Kyne, Matthew Bedore, Sanjay Menon
  • ANIMAL AND HUMAN ANTI-MALARIAL AGENTS
    Publication number: 20200330469
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 22, 2020
    Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK
  • Animal and human anti-malarial agents
    Patent number: 10736899
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: August 11, 2020
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk
  • ANIMAL AND HUMAN ANTI-MALARIAL AGENTS
    Publication number: 20190365766
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Application
    Filed: August 14, 2019
    Publication date: December 5, 2019
    Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK
  • Animal and human anti-trypanosomonal and anti-leishmania agents
    Patent number: 10420772
    Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk, Michael John Witty
  • Animal and human anti-malarial agents
    Patent number: 10420771
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologs, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk
  • ANIMAL AND HUMAN ANTI-MALARIAL AGENTS
    Publication number: 20180280398
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK
  • ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
    Publication number: 20180280399
    Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK, Michael John WITTY
  • Animal and human anti-malarial agents
    Patent number: 10016436
    Abstract: Provided herein are Purine Comounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: July 10, 2018
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk
  • Animal and human anti-trypanosomonal and anti-leishmania agents
    Patent number: 10010555
    Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: July 3, 2018
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk, Michael John Witty
  • ANIMAL AND HUMAN ANTI-MALARIAL AGENTS
    Publication number: 20170348316
    Abstract: Provided herein are Purine Comounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK
  • ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
    Publication number: 20170348315
    Abstract: Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.
    Type: Application
    Filed: June 1, 2017
    Publication date: December 7, 2017
    Inventors: Stacie S. CANAN, Natalie Anne HAWRYLUK, Michael John WITTY
  • Tricyclic inhibitors of poly(ADP-ribose) polymerases
    Patent number: 7429578
    Abstract: Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: September 30, 2008
    Assignees: Agouron Pharmaceuticals, Inc., Cancer Research Campaign Technology Limited
    Inventors: Stephen Evan Webber, Stacie S. Canan-Koch, Jayashree Tikhe, Lars Henrik Thoresen
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Patent number: 7179918
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: February 20, 2007
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Benjamin J. Burke, Tanya M. Jewell, David J. Kucera, Maria Angelica Linton, Lennert J. Mitchell, Jr., Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Jeffrey J. Machak, Tod Holler, Sean T. Murphy, Michael Melnick, Vara Prasad Josyula
  • Tricyclic inhibitors of poly(ADP-ribose) polymerases
    Patent number: 6977298
    Abstract: Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: December 20, 2005
    Assignees: Agouron Pharmacetucals, Inc., Cancer Research Campaign Technology Limited
    Inventors: Stephen Evan Webber, Stacie S. Canan-Koch, Jayashree Tikhe, Lars Henrik Thoresen
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Patent number: 6953858
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: October 11, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria Angelica Linton, Jeffrey J. Machak, Lennert J. Mitchell, Jr., Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
    Publication number: 20030225071
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: December 4, 2003
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Fredrick E. Boyer, Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria A. Linton, Jeffrey J. Machak, Lennert J. Mitchell, Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick